Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.66 |
| ▸ | BCL6 | P41182 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395800 | 0.89 | KIF11 (0.52) | KIF11SMYD3KDM4EMEN1LMNA | |
| SCHEMBL16208502 | 0.87 | KIF11 (0.67) | KIF11DDB1CRBN | |
| SCHEMBL16208518 | 0.80 | KIF11 (1.00) | KIF11PTK2BGAA | |
| SCHEMBL18312045 | 0.79 | ULK1 (0.54) | KIF11SMYD3DDB1CRBN | |
| Hydrochloric Acid SCHEMBL18302922 | 0.78 | ULK1 (0.53) | KIF11SMYD3DDB1CRBN | |
| SCHEMBL22660 | 0.78 | AHR (0.61) | SMYD3GRIA1CACNG8GAAAHR | |
| SCHEMBL28837814 | 0.78 | KIF11 (0.63) | KIF11BCL6SMYD3GRIA1PTK2B | |
| SCHEMBL10714806 | 0.78 | TDP2 (0.69) | GRIA1CACNG8AHRPGRCRBN | |
| SCHEMBL28119242 | 0.78 | AHR (0.68) | KIF11BCL6SMYD3PTK2BGAA | |
| Hydrochloric Acid SCHEMBL15206761 | 0.76 | AHR (0.59) | SMYD3GRIA1CACNG8GAAAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | disclosed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| CN-101056632-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-10-17 | — | — | CN | disclosed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | KIF11 1787/4885BCL6 838/4885SMYD3 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.